Short-Dated Bullish Options Flow in Regeneron (REGN) Following 3Q Earnings Beat -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Regeneron Pharma (REGN) PT Lowered to $465 at Jefferies
November 9, 2017 8:15 AM ESTJefferies lowered its price target on Regeneron Pharma (NASDAQ: REGN) to $465.00 (from $500.00) while maintaining a Hold rating.
... MoreRegeneron (REGN) Tops Q3 EPS by 14c, Beats on Revenues
November 8, 2017 6:36 AM ESTRegeneron (NASDAQ: REGN) reported Q3 EPS of $3.99, $0.14 better than the analyst estimate of $3.85. Revenue for the quarter came in at $1.5 billion versus the consensus estimate of $1.46 billion.
Third quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 12% to $953 million versus third quarter 2016Third... MoreRegeneron (REGN) and Sanofi (SNY) to Present New Analyses from Praluent Injection ODYSSEY Clinical Trial Program at AHA
November 7, 2017 8:26 AM ESTRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new data analyses from the Praluent® (alirocumab) Injection ODYSSEY clinical trial program will be presented at the American Heart Association (AHA) Scientific Sessions 2017, November 11-15, in Anaheim, CA.
New analyses from the ODYSSEY ESCAPE trial evaluating treatment... More
